{
  "id": 14947324,
  "title": "Stifel reiterates Glaukos stock rating on strong iDose growth",
  "url": "https://urgent.news/2026/10/16/stifel-reiterates-glaukos-stock-rating-on-strong-idose-growth",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-16T11:58:54.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/stifel-reiterates-glaukos-stock-rating-on-strong-idose-growth-93CH-4953945"
  },
  "original_language": "en",
  "account": "Stifel has reaffirmed its Buy rating and $190 price target for Glaukos Corporation (NYSE:GKOS) shares, citing strong growth prospects in its iDose product line. The stock is currently trading at $165.60, implying a 15% upside potential to reach the target price. According to InvestingPro data, a third-quarter 2026 analysis of iDose sales suggests a range of $81 million to $85 million, with better-than-expected Medicare Advantage and commercial payer results suggesting continued growth in 2027. Survey responses indicated strong positive patient outcomes for iDose, and the firm highlighted excitement for key innovations such as iDose TREX and potential in-office administration. While Stifel noted that Epioxa revenues may be strong in the third quarter of 2026, they believe its impact may be less significant than initially anticipated. Despite this, Glaukos reported a 49.5% year-over-year revenue increase for Q2 2026, surpassing H.C. Wainwright's projection of $151.5 million. Several other analyst firms have also increased their price targets for Glaukos, with H.C. Wainwright raising its target to $195 and Needham to $201, both maintaining a Buy rating. Stifel's optimistic outlook is supported by a projected $1.0 billion or more in revenue for Glaukos by 2027, reflecting strong market confidence in the company's future performance.",
  "summary": null,
  "key_points": [
    "Stifel reaffirms Buy rating and $190 price target for Glaukos (GKOS)",
    "iDose product line expected to reach $81M-$85M in Q3 2026 sales",
    "Strong Medicare Advantage and commercial payer results anticipated for 2027"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Stifel reiterates Valmont Industries stock Buy rating at $678",
        "url": "https://urgent.news/2026/10/16/stifel-reiterates-valmont-industries-stock-buy-rating-at-678",
        "published": "2026-10-16T11:58:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}